Welcome to our dedicated page for ABPRO HLDGS SEC filings (Ticker: ABP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scientific jargon, clinical trial tables, and SPAC merger details make Abpro’s disclosures a heavy lift for even seasoned biotech analysts. If you have ever searched for “Abpro SEC filings explained simply” or wondered why a single S-4 spans hundreds of pages, you know the challenge: crucial information on trial milestones, partnership economics, and dilution risk is buried deep within technical exhibits.
Stock Titan solves this problem. Our AI reads every new document from the moment it hits EDGAR and turns it into plain-English insights you can act on. Want the next “Abpro quarterly earnings report 10-Q filing” distilled into key R&D spend trends? Need “Abpro insider trading Form 4 transactions” or “Abpro executive stock transactions Form 4” delivered in real time before market open? Looking for an at-a-glance view of how the S-4 merger impacts share count? We have it covered.
Here is what you will find on this page:
- “Abpro annual report 10-K simplified” – AI-powered summaries spotlighting pipeline progress and cash runway.
- Side-by-side “Abpro earnings report filing analysis” across quarters to track clinical spend versus capital raises.
- Instant alerts for “Abpro Form 4 insider transactions real-time” so you can monitor buys or sells ahead of data readouts.
- Clear explanations of every 8-K material events – search “Abpro 8-K material events explained” and land here.
- Drill into the “Abpro proxy statement executive compensation” section to see how milestones drive leadership incentives.
Whether you are comparing ABP-102 trial updates, auditing collaboration revenue from Celltrion, or simply understanding Abpro SEC documents with AI, Stock Titan’s real-time coverage turns complex antibody filings into actionable intelligence in minutes, not hours.
Abpro Holdings, Inc. has filed a prospectus supplement that incorporates its Form 10-Q for the quarter ended September 30, 2025. The company reported a net loss of $1.7 million for the quarter and $8.5 million for the nine months, driven mainly by research and development and general and administrative expenses. Cash was only $328 thousand as of September 30, 2025, compared with current liabilities of $17.3 million, resulting in a stockholders’ deficit of $15.6 million. Management concluded there is substantial doubt about Abpro’s ability to continue as a going concern and plans to seek additional equity or debt financing and collaborations. The company implemented a 1-for-30 reverse stock split effective October 31, 2025 and remains under a Nasdaq panel exception through March 30, 2026 after prior noncompliance with minimum bid price, market value of publicly held shares and market value of listed securities requirements.
Abpro Holdings, Inc. filed a Form S-1 for the offer and resale of up to 9,775,017 registered shares of Common Stock issuable under its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. YA may resell these shares from time to time.
The company will not receive proceeds from YA’s resales. Abpro may receive up to $50,000,000 in aggregate gross proceeds from sales of Common Stock to YA under the SEPA, at Abpro’s discretion and subject to SEPA terms.
The filing notes potential market impact from these sales. As context, the shares registered represent approximately 361% of Common Stock outstanding as of November 6, 2025, when 2,705,061 shares were outstanding. The offering table indicates 12,480,078 shares outstanding after the offering. Abpro effected a 1-for-30 reverse stock split on October 31, 2025. The Common Stock and Public Warrants trade on Nasdaq as “ABP” and “ABPWW”.
Abpro Holdings (ABP) filed an 8-K/A amending Item 7.01 to replace the press release furnished as Exhibit 99.1 dated November 4, 2025. The company states no other changes were made to the original report.
The information under Item 7.01 and Exhibit 99.1 is furnished, not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.
Abpro Holdings (ABP) reported that it and Celltrion will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The meeting runs November 6–10, 2025 at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
The disclosure was furnished under Item 7.01 (Regulation FD), and a related press release was provided as Exhibit 99.1. This update focuses on scientific progress and does not include financial results or transaction details.
Abpro Holdings, Inc. announced a one-for-thirty reverse stock split that became effective at 5:01 p.m. on October 31, 2025. The company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Global Market on November 3, 2025.
The disclosure was made under Regulation FD via an 8-K, with a press release furnished as Exhibit 99.1.
Abpro Holdings (ABP) announced a one-for-thirty reverse stock split of its common stock, effective at 5:01 p.m. on October 31, 2025. Every 30 shares will be combined into one share, with no change to par value. No fractional shares will be issued; holdings will be rounded up to the next whole share.
Following the split, common shares outstanding will be proportionally reduced from 81,150,000 to approximately 2,705,000. Outstanding stock options and warrants, and their exercise prices, will be adjusted to reflect the new ratio. The company’s transfer agent, Continental Stock Transfer & Trust Company, will handle recordholder communications, while broker-held positions will adjust automatically.
The common stock will begin trading on a split-adjusted basis on November 3, 2025, under the ticker ABP. The new CUSIP for the common stock will be 000847202.
Abpro Holdings (ABP) reported a Nasdaq compliance update. On October 14, 2025, the company received notice that it had not regained compliance with two Nasdaq Global Market standards: the Market Value of Publicly Held Shares requirement of $15,000,000 and the Market Value of Listed Securities requirement of $50,000,000, following a 180-day cure period that ended October 7, 2025.
A hearing before an independent Nasdaq Hearings Panel is scheduled for October 30, 2025, where Abpro plans to present its approach to address the Minimum Bid Price Requirement, MVPHS, and MVLS. Delisting action is stayed pending the Panel’s decision, so ABP common stock and warrants remain listed for now. The company cautioned there is no assurance the Panel will grant continued listing or that compliance can be demonstrated within any extension.
Abpro Holdings reported results of its 2025 annual meeting of stockholders. A 1-for-30 reverse stock split was approved. Ian McDonald was elected as a Class I director until the 2028 annual meeting, and Wolf & Company, P.C. was ratified as independent auditor for the fiscal year ending December 31, 2025.
Voting details: Ian McDonald received 30,544,989 votes for, with 8,122,953 withheld and 10,863,999 broker non-votes. Auditor ratification received 48,873,247 votes for, 380,320 against, and 278,374 abstentions. The reverse stock split at a ratio of 1-for-30 was approved with 26,657,935 votes for.
On the record date, there were 80,166,667 shares outstanding. A quorum was established with 49,531,941 votes represented, approximately 61.8% of eligible votes.
FAQ
What is the current stock price of ABPRO HLDGS (ABP)?
What is the market cap of ABPRO HLDGS (ABP)?
